Serum adiponectin is associated with fasting serum C-peptide in non-obese diabetic patients

Diabetes Research and Clinical Practice

Volumn 72, Issue 3, 2006, Pages 302-307

  Furuta, Machi ^a   Tamai, Masanori ^b   Hanabusa, Tadashi ^b   Yamamoto, Yasuhisa ^c   Nanjo, Kishio ^a   Sanke, Tokio ^a  

^a WAKAYAMA MEDICAL UNIVERSITY   (Japan)

^b Department of Medicine in Hidaka General Hospital ^*  (Japan)

^c Diabetic Center in Han nan City Hospital   (Japan)

Author keywords

Adiponectin; C peptide; Pancreatic cell function

Indexed keywords

ADIPONECTIN; C PEPTIDE; INSULIN;

ADULT; ARTICLE; CELL FUNCTION; CONTROLLED STUDY; CORRELATION ANALYSIS; DOSE RESPONSE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; MAJOR CLINICAL STUDY; MALE; MULTIPLE REGRESSION; MULTIVARIATE ANALYSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS INSUFFICIENCY; PANCREAS ISLET BETA CELL; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL;

ADIPONECTIN; ADIPOSITY; BLOOD GLUCOSE; BODY MASS INDEX; C-PEPTIDE; DIABETES MELLITUS; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; FASTING; FEMALE; GLUCOSE TOLERANCE TEST; HUMANS; INSULIN; INSULIN RESISTANCE; INSULIN-SECRETING CELLS; MALE; OBESITY; REGRESSION ANALYSIS; SEX CHARACTERISTICS; STATISTICS; STATISTICS AS TOPIC;

EID: 33646590317     PISSN: 01688227     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.diabres.2005.10.026     Document Type: Article

References (30)

1. Shimada K., Miyazaki T., and Daida H. Adiponectin and atherosclerotic disease. Clin. Chem. Acta. 344 (2004) 1-12
2. Pischon T., Girman C.J., Hotamisligil G.S., Rifai N., Hu F.B., and Rimm E.B. Plasma adiponectin levels and risk of myocardial infarction in men. JAMA 291 (2004) 1730-1737
3. Ohashi K., Kihara S., Funahashi T., Nakamura T., Sumitsuji S., Kawamoto T., et al. Adiponectin I164T mutation is associated with the metabolic syndrome and coronary artery disease. J. Am. Coll. Cardiol. 43 (2004) 1195-1200
4. Ouchi N., Kihara S., Arita Y., Okamoto Y., Maeda K., Kuriyama H., et al. Adiponectin, an adipocyte-derived plasma protein, inhibits endothelial NF-[kappa]B signaling through a cAMP-dependent pathway. Circulation 102 (2000) 1296-1301
5. Pellme F., Smith U., Funahashi T., Matsuzawa Y., Brekke H., Wiklund O., et al. Circulating adiponectin level are reduced in non-obese but insulin-resistant first-degree relatives of type 2 diabetic patients. Diabetes 52 (2003) 1182-1186
6. Yatagai T., Nagasaki S., Taniguti A., Fukushima M., Nakamura T., Kuroe A., et al. Hypoadiponectinemia is associated with visceral fat accumulation and insulin resistance in Japanese men with type 2 diabetes mellitus. Metabolism 52 (2003) 1274-1278
7. Arita Y., Kihara S., Ouchi N., Takahashi M., Maeda K., Miyagawa J., et al. Paradoxical decrease of an adipose-specific-protein, adiponectin, in obesity. Biochem. Biophys. Res. Commun. 257 (1999) 79-83
8. Weyer C., Funahashi T., Tanaka S., Hotta K., Matsuzawa Y., Pratley R.E., et al. Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J. Clin. Endocrinol. Metab. 86 (2001) 1930-1935
9. Maeda N., Shimomura I., Kishida K., Nishizawa H., Matsuda M., Nagaretani H., et al. Diet-induced insulin resistance in mice lacking adiponectin/ACRP30. Nat. Med. 8 (2002) 731-737
10. Hotta K., Funahashi T., Arita Y., Takahashi M., Matsuda M., Okamoto Y., et al. Plasma concentration of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. Arterioscler. Thromb. Vasc. Biol. 20 (2000) 1595-1599
11. National Cholesterol Education Program. Executive summary of the third report of national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adults Treatment Panel III). JAMA 285 (2001) 2486-2497
12. Hulthe J., Hulten L.M., and Fagerberg B. Low adipocyte-derived plasma protein adiponectin concentrations are associated with the metabolic syndrome and small dense low-density lipoprotein particles: atherosclerosis and insulin resistance study. Metabolism 52 (2003) 1612-1614
13. Krokoff J., Funahashi T., Stehouwer C.D.A., Schalkwijk C.G., Tanaka S., Matsuzawa Y., et al. Inflammatory markers, adiponectin, and risk of type 2 diabetes in the Pima India. Diabetes Care 26 (2003) 1745-1751
14. Tschritter O., Fritsche A., Thamer C., Haap M., Shirkavand F., Rahe S., et al. Plasma adiponectin concentrations predict insulin sensitivity of both glucose and lipid metabolism. Diabetes 52 (2003) 239-243
15. Snehalatha C., Mukesh B., Simon M., Viswanathan V., Haffner S., and Ramachandran A. Plasma adiponectin is an independent predictor of type 2 diabetes in Asian Indians. Diabetes Care 26 (2003) 3226-3229
16. Daiman M., Oizumi T., Saitoh T., Kameda W., Hirata A., Yamaguchi H., et al. Decreased serum levels of adiponectin are a risk actor for the progression to type 2 diabetes in the Japanese population. Diabetes care 26 (2003) 2015-2020
17. Vozarova B., Stefan N., Lindsay R.S., Krakoff J., Knowler W.C., Funahashi T., et al. Low plasma adiponectin concentrations do not predict weight gain in humans. Diabetes 51 (2002) 2964-2967
18. Spranger J., Kroke A., Mohlig M., Bergmann M.M., Ristow M., Boeing H., et al. Adiponectin and protection against type 2 diabetes mellitus. Lancet 61 (2003) 226-228
19. Mannucci E., Ognibene A., Cremasco F., Dicembrini I., Bardini G., Brogi M., et al. Plasma adiponectin and hyperglycemia in diabetic patients. Clin. Chem. Lab. Med. 41 (2003) 1131-1135
20. Nonogaki K., Kumano H., Ootsuka Y., Takeuchi A., Nonogaki N., and Kuboki T. Clinical worth of adiponectin levels in obesity and glycemic control of Japanese type 2 diabetic patients. Diabetes Care 26 (2003) 3198
21. Stefan N., Stumvoll M., Vozarova B., Weyer C., Funahashi T., Matyuzawa Y., et al. Plasma adiponectin and endogenous glucose production in humans. Diabetes Care 26 (2003) 3315-3319
22. Tsou P.-L., Jiang Y.-D., Chang C.-C., Wei J.-N., Sung F.-C., Lin C.-C., et al. Sex-related differences between adiponectin and insulin resistance in schoolchildren. Diabetes Care 27 (2004) 308-313
23. Bajaj M., Suraamornkul S., Piper P., Hardies L.J., Glass L., Cersosimo E., et al. Decreased plasma adiponectin concentrations are closely related to hepatic fat content and hepatic insulin resistance in pioglitazone-treated type 2 diabetic patients. J. Clin. Endocrinol. Metab. 89 (2004) 200-206
24. Hirose H., Kawai T., Yamamoto Y., Taniyama M., Tomita M., Matsubara K., et al. Effects of pioglitazone on metabolic parameters, body fat distribution, and serum adiponectin levels in Japanese male patients with type 2 diabetes. Metabolism 51 (2002) 314-317
25. Yu J.G., Javorschi S., Hevener A.L., Kruszynska Y.T., Norman R.A., Sinha M., et al. The effect of thiazolidinediones on plasma adiponectin level in normal, obese and type 2 diabetic subjects. Diabetes 51 (2002) 2968-2974
26. Haffner S.M., Miettinen H., and Stern M.P. The homeostasis model in San Antonio Heart Study. Diabetes Care 20 (1997) 1087-1092
27. Nishizawa H., Shimomura I., Kishida K., Maeda N., Kuriyama H., Nagaretani H., et al. Androgens decrease plasma adiponectin, an insulin-sensitizing adipocyte-derived protein. Diabetes 51 (2002) 2734-2741
28. Perseghin G., Lattuada G., Danna M., Sereni L.P., Maffi P., DeCobelli F., et al. Insulin resistance, intramyocellular lipid content, and plasma adiponectin in patients with type 1 diabetes. Am. J. Physiol. Endocrinol. Metab. 285 (2003) E1174-E1181
29. Imagawa A., Funahashi T., Nakamura T., Moriwaki M., Tanaka S., Nishizawa H., et al. Elevated serum concentration of adipose-derived factor, adiponectin, in patients with type 1 diabetes. Diabetes Care 25 (2002) 1665-1666
30. Clarke K.J., Zhong Q., Schwartz D.D., Coleman E.S., Kemppainen R.J., and Judd R.L. Regulation of adiponectin secretion by endothelin-1. Biochem. Biophys. Res. Commun. 312 (2003) 945-949